Drug Sponsors

Johnson & Johnson to acquire Aragon Pharmaceuticals

Monday, June 17, 2013 01:53 PM

Johnson & Johnson has announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.

More... »

Athera Biotechnologies awarded collaborative research grant

Monday, June 17, 2013 01:45 PM

Athera Biotechnologies said future development costs of its fully human antibody PC-mAb, until proof-of-concept, will be co-funded by the European Union’s Seventh Framework Program for Research (FP7) through a collaborative research grant.

More... »

Elan to proceed with formal sale process

Friday, June 14, 2013 02:38 PM

Elan has announced it is proceeding with a formal sale process in light of the expressions of interest received to date. As part of this process, Royalty Pharma will be invited to participate. Elan has urged shareholders not to tender into the current Royalty Pharma offer.

More... »

Pfizer announces Zoetis split-off plan

Friday, June 14, 2013 01:42 PM

Pfizer intends to split off its remaining interest in Zoetis through an exchange offer. Zoetis, formerly Pfizer's animal health business, completed its initial public offering (IPO) in February 2013. Pfizer shareholders can exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer.

More... »

HHS partners with GSK for new antibiotics

Wednesday, June 12, 2013 02:19 PM

GlaxoSmithKline and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), are collaborating to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

More... »

Almac expands, to create 229 jobs

Wednesday, June 12, 2013 02:12 PM

Craigavon-based Almac has announced a commercial manufacturing expansion. With the recent completion of a non-GMP drug development facility at the Craigavon site, this expansion represents a total investment of $10.3 million, including financial support from Invest Northern Ireland.  Up to 229 jobs will be created across both projects over the next three years.

More... »

AstraZeneca acquires Pearl Therapeutics

Tuesday, June 11, 2013 01:02 PM

AstraZeneca has acquired Pearl Therapeutics, a privately held company focused on the development of inhaled small-molecule therapeutics for respiratory disease.

More... »

BioLineRx licenses Hepatitis C treatment to CCTQ

Tuesday, June 11, 2013 12:00 PM

Drug development company BioLineRx has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical (CCTQ), a Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an oral treatment for the Hepatitis C virus (HCV).

More... »

Boehringer Ingelheim, Zhangjiang to open biopharmaceuticals facility in China

Tuesday, June 11, 2013 10:00 AM

Boehringer Ingelheim and Zhangjiang Biotech & Pharmaceutical Base Developmentof Pudong, Shanghai have allied to build a cGMP biopharmaceuticals facility. The site will provide development and clinical services to Chinese and multi-national customers. It will utilize mammalian cell culture technology.

More... »

Impax Laboratories to cut workforce

Friday, June 7, 2013 01:57 PM

Impax Laboratories, a technology-based specialty pharmaceutical company, will implement a reduction in its workforce as a part of efforts to streamline its operations in response to the need to reduce expenses and adapt to changing market conditions. The reduction primarily affects manufacturing operations and is intended to reduce Impax's cost structure and scale the organization appropriately for its current needs.

More... »